Events

    • DEC 03 2015

    Presentations on ONC201 at the 2015 ASH Annual Meeting

    Oncoceutics, Inc. announces that multiple abstracts will be presented on its lead compound, ONC201, at the 2015 annual meeting of the American Society of Hematology (ASH) in Orlando. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response Presenter: Jo Ishizawa Session time & date: Saturday, December

    • NOV 08 2015

    Presentation on ONC201 at the AACR Molecular Targets and Cancer Therapeutics Conference

    Dr. Mark Stein, Principal Investigator of the first-in-man trial will discuss the results of the first-in-human dose escalation study of oral ONC201 in advanced solid tumors at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, Massachusetts and will be published in the online Proceedings. Session ID:                           Poster Session C Session Title:                       New Molecular Targets Session Date and

    • SEP 06 2015

    Oncoceutics to Present at the BIO Investor Forum

    Oncoceutics has been selected to present on the Discovery Track at the 14th Annual Bio Investor Forum, which will take place on October 20-21, 2015, in San Francisco. Oncoceutics is delighted to have been chosen to take part in the BIO Investor Forum, which is designed to “explore investment trends and opportunities in life sciences, with a

    • MAY 30 2015

    First-in-Man ONC201 Trial to be Presented at 2015 ASCO Meeting

    Dr. Mark Stein, Principal Investigator of the first-in-man trial will discuss the first-in-human dose escalation study of oral ONC201 in advanced solid tumors at the 2015 ASCO Annual Meeting.